Biomarkers of Sepsis

키워드

참고문헌 (95)

1. Levy MM, "The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis", Intensive Care Med, 36, pp.222~231 (2010)
2. Ranieri VM, "PROWESSSHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock", N Engl J Med, 366, pp.2055~2064 (2012)
3. Vincent JL, "The rise and fall of drotrecogin alfa (activated)", Lancet Infect Dis, 12, pp.649~651 (2012)
4. Guntupalli K, "TLF LF-0801 Investigator Group. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis", Crit Care Med, 41, pp.706~716 (2013)
5. McCulloh R, "Human recombinant lactoferrin for sepsis: too good to be true?", Crit Care Med, 41, pp.908~909 (2013)
6. Opal SM, "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial", JAMA, 309, pp.1154~1162 (2013)
7. Dellinger RP, "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012", Crit Care Med, 41, pp.580~637 (2013)
8. 최정현, "근거 중심의 패혈증 치료에 대한 최신 지견", Infection and Chemotherapy, 40(2), pp.67~75 (2008), 대한감염학회
9. Sands KE, "Epidemiology of sepsis syndrome in 8 academic medical centers", JAMA, 278, pp.234~240 (1997)
10. Vincent JL, "Sepsis in European intensive care units: results of the SOAP study", Crit Care Med, 34, pp.344~353 (2006)
11. Hotchkiss RS, "The pathophysiology and treatment of sepsis", N Engl J Med, 348, pp.138~150 (2003)
12. Hotchkiss RS, "Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach", Lancet Infect Dis, 13, pp.260~268 (2013)
13. Unsinger J, "IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis", J Immunol, 184, pp.3768~3779 (2010)
14. Meisel C, "Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression:a double-blind, randomized, placebocontrolled multicenter trial", Am J Respir Crit Care Med, 180, pp.640~648 (2009)
15. Boomer JS, "Immunosuppression in patients who die of sepsis and multiple organ failure", JAMA, 306, pp.2594~2605 (2011)
16. Biomarkers Definitions Working Group, "Biomarkers and surrogate endpoints: preferred definitions and conceptual framework", Clin Pharmacol Ther, 69, pp.89~95 (2001)
17. Pierrakos C, "Sepsis biomarkers: a review", Crit Care, 14, pp.R15~ (2010)
18. Calvano SE, "Res. Program. A networkbased analysis of systemic inflammation in humans", Nature, 437, pp.1032~1037 (2005)
19. Marshall JC, "Biomarkers of sepsis", Crit Care Med, 37, pp.2290~2298 (2009)
20. Samraj RS, "Role of biomarkers in sepsis care", Shock, 40, pp.358~365 (2013)
21. Pettilä V, "Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis", Intensive Care Med, 28, pp.1220~1225 (2002)
22. Oberholzer A, "Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis", Shock, 23, pp.488~493 (2005)
23. Pinsky MR, "Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality", Chest, 103, pp.565~575 (1993)
24. Qiu P, "The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death", Expert Opin Investig Drugs, 20, pp.1555~1564 (2011)
25. Rice TW, "Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab)in severe sepsis", Crit Care Med, 34, pp.2271~2281 (2006)
26. Lvovschi V, "Cytokine profiles in sepsis have limited relevance for stratifying patients in the emergency department:a prospective observational study", PLoS One, 6, pp.e28870~ (2011)
27. Bozza FA, "Cytokine profiles as markers of disease severity in sepsis:a multiplex analysis", Crit Care, 11, pp.R49~ (2007)
28. Andaluz-Ojeda D1, "A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis", Cytokine, 57, pp.332~336 (2012)
29. Jerala R, "Structural biology of the LPS recognition", Int J Med Microbiol, 297, pp.353~363 (2007)
30. Zweigner J, "High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes", Blood, 98, pp.3800~3808 (2001)
31. Gaïni S, "Procalcitonin, lipopolysaccharide-binding protein, interleukin-6and C-reactive protein in community-acquired infections and sepsis: a prospective study", Crit Care, 10, pp.R53~ (2006)
32. Opal SM, "Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock", J Infect Dis, 180, pp.1584~1589 (1999)
33. Sakr Y, "Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis?", Crit Care Med, 36, pp.2014~2022 (2008)
34. Choi JH, "Pathogenesis of sepsis and concepts of immunotherapy", Korean J Infect Dis, 32, pp.148~157 (2000)
35. Sundén-Cullberg J, "Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock", Crit Care Med, 33, pp.564~573 (2005)
36. Hatada T, "Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation", Thromb Haemost, 94, pp.975~979 (2005)
37. Gibot S, "High-mobility group box 1 protein plasma concentrations during septic shock", Intensive Care Med, 33, pp.1347~1353 (2007)
38. Petrovsky N, "Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator", Immunol Cell Biol, 81, pp.137~143 (2003)
39. Calandra T, "Protection from septic shock by neutralization of macrophage migration inhibitory factor", Nat Med, 6, pp.164~170 (2000)
40. Bozza FA, "Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis", Shock, 22, pp.309~313 (2004)
41. Tillett WS, "Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus", J Exp Med, 52, pp.561~571 (1930)
42. Vincent JL, "Biomarkers in the critically ill patient: C-reactive protein", Crit Care Clin, 27, pp.241~251 (2011)
43. Müller B, "Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit", Crit Care Med, 28, pp.977~983 (2000)
44. Selberg O, "Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6", Crit Care Med, 28, pp.2793~2798 (2000)
45. Suprin E, "Procalcitonin: a valuable indicator of infection in a medical ICU?", Intensive Care Med, 26, pp.1232~1238 (2000)
46. Simon L, "Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and metaanalysis", Clin Infect Dis, 39, pp.206~217 (2004)
47. Póvoa P, "C-reactive protein as a marker of infection in critically ill patients", Clin Microbiol Infect, 11, pp.101~108 (2005)
48. Schmit X, "The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis", Infection, 36, pp.213~219 (2008)
49. Assicot M, "High serum procalcitonin concentrations in patients with sepsis and infection", Lancet, 341, pp.515~518 (1993)
50. O'Grady NP1, "Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America", Crit Care Med, 36, pp.1330~1349 (2008)
51. Wacker C, "Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis", Lancet Infect Dis, 13, pp.426~435 (2013)
52. Reinhart K, "Biomarkers in the critically ill patient:procalcitonin", Crit Care Clin, 27, pp.253~263 (2011)
53. Schuetz P, "Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study", Eur J Clin Invest, 40, pp.376~381 (2010)
54. Kopterides P, "Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials", Crit Care Med, 38, pp.2229~2241 (2010)
55. Mikkelsen ME1, "Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock", Crit Care Med, 37, pp.1670~1677 (2009)
56. Wacharasint P, "Normal-range blood lactate concentration in septic shock is prognostic and predictive", Shock, 38, pp.4~10 (2012)
57. Shapiro NI, "Serum lactate as a predictor of mortality in emergency department patients with infection", Ann Emerg Med, 45, pp.524~528 (2005)
58. Kruse O, "Blood lactate as a predictor for in-hospital mortality in patients admitted acutely to hospital: a systematic review", Scand J Trauma Resusc Emerg Med, 19, pp.74~ (2011)
59. Khosravani H1, "Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill", Crit Care, 13, pp.R90~ (2009)
60. Claridge JA, "Persistent occult hypoperfusion is associated with a significant increase in infection rate and mortality in major trauma patients", J Trauma, 48, pp.8~14 (2000)
61. Nguyen HB, "Early lactate clearance is associated with improved outcome in severe sepsis and septic shock", Crit Care Med, 32, pp.1637~1642 (2004)
62. Linscheid P, "Autocrine", paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue, 2005, pp.146, 2699~2708
63. Hinson JP, "Adrenomedullin, a multifunctional regulatory peptide", Endocr Rev, 21, pp.138~167 (2000)
64. Christ-Crain M, "Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study", Crit Care, 9, pp.R816~R824 (2005)
65. Al Shuaibi M, "Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies", Clin Infect Dis, 56, pp.943~950 (2013)
66. Suberviola B, "Hospital mortality prognostication in sepsis using the new biomarkers suPAR and pro-ADM in a single determination on ICU admission", Intensive Care Med, 39, pp.1945~1952 (2013)
67. Icardi M, "CD64 index provides simple and predictive testing for detection and monitoring of sepsis and bacterial infection in hospital patients", J Clin Microbiol, 47, pp.3914~3919 (2009)
68. Cid J, "Neutrophil CD64: diagnostic accuracy and prognostic value in patients presenting to the emergency department", Eur J Clin Microbiol Infect Dis, 30, pp.845~852 (2011)
69. Gros A, "The sensitivity of neutrophil CD64 expression as a biomarker of bacterial infection is low in critically ill patients", Intensive Care Med, 38, pp.445~452 (2012)
70. Cid J, "Neutrophil CD64 expression as marker of bacterial infection:a systematic review and meta-analysis", J Infect, 60, pp.313~319 (2010)
71. Bouchon A, "TREM-1 amplifies inflammation and is a crucial mediator of septic shock", Nature, 410, pp.1103~1107 (2001)
72. Gibot S, "Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis", Crit Care, 9, pp.485~489 (2005)
73. Ford JW, "TREM and TREM-like receptors in inflammation and disease", Curr Opin Immunol, 21, pp.38~46 (2009)
74. Gibot S, "Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis", Ann Intern Med, 141, pp.9~15 (2004)
75. Zhang J, "Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study", BMC Infect Dis, 11, pp.53~ (2011)
76. Jiyong J, "Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis", Intensive Care Med, 35, pp.587~595 (2009)
77. Wu Y, "Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis", Crit Care, 16, pp.R229~ (2012)
78. Jeong SJ, "MEASUREMENT OF PLASMA sTREM-1 IN PATIENTS WITH SEVERE SEPSIS RECEIVING EARLY GOAL-DIRECTED THERAPY AND EVALUATION OF ITS USEFULNESS", SHOCK, 37, pp.574~578 (2012), LIPPINCOTT WILLIAMS & WILKINS
79. Ploug M, "Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol", J Biol Chem, 266, pp.1926~1933 (1991)
80. Blasi F, "uPAR: a versatile signalling orchestrator", Nat Rev Mol Cell Biol, 3, pp.932~943 (2002)
81. Koch A, "Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients", Crit Care, 15, pp.R63~ (2011)
82. Kofoed K, "Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections:a prospective study", Crit Care, 11, pp.R38~ (2007)
83. Koch A, "Why high suPAR is not super--diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU", Crit Care, 15, pp.1020~ (2011)
84. Backes Y, "Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection:a systematic review", Intensive Care Med, 38, pp.1418~1428 (2012)
85. Donadello K, "suPAR as a prognostic biomarker in sepsis", BMC Med, 10, pp.2~ (2012)
86. Haupt TH, "Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient:a prospective observational study", Crit Care, 16, pp.R130~ (2012)
87. Uusitalo-Seppälä R, "Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study", J Intern Med, 272, pp.247~256 (2012)
88. David S, "Mending leaky blood vessels: the angiopoietin-Tie2 pathway in sepsis", J Pharmacol Exp Ther, 345, pp.2~6 (2013)
89. Fiedler U, "Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation", Nat Med, 12, pp.235~239 (2006)
90. Ricciuto DR, "Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis", Crit Care Med, 39, pp.702~710 (2011)
91. Gibot S, "Combination biomarkers to diagnose sepsis in the critically ill patient", Am J Respir Crit Care Med, 186, pp.65~71 (2012)
92. Shapiro NI, "A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis", Crit Care Med, 37, pp.96~104 (2009)
93. Peres Bota D, "Infection Probability Score (IPS): A method to help assess the probability of infection in critically ill patients", Crit Care Med, 31, pp.2579~2584 (2003)
94. Kofoed K, "Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor", Eur J Clin Microbiol Infect Dis, 27, pp.375~383 (2008)
95. Harbarth S, "Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis", Am J Respir Crit Care Med, 164, pp.396~402 (2001)

관련 논문AI추천